Feedback / Questions
AGS-499 - Neuromagen Pharma
https://www.biospace.com/article/neuromagen-pharma-ltd-receives-fda-orphan-drug-designation-for-its-ags-499-drug-candidate-to-slow-the-progression-of-als-amyotrophic-lateral-sclerosis-/
 
May 7, 2022
 
SHARE THIS
  • Print
  • Email
  • More sharing
    Reddit
    StumbleUpon
    Delicious